# Glycopyrrolate

## Glycopyrodyn inj 0.2mg/1mL

| TAH Drug Code      | [IGLYC](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IGLYC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Preoperatively to inhibit salivation & excessive secretions of the respiratory tract; reversal of neuromuscular blockade; control of upper airway secretions; adjunct in treatment of peptic ulcer.                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | Preoperative Adult & children 1 month-12 years 0.002 mg/pound body weight (0.01 mL) IM 30-60 mins before procedure or to be administered with preanesthetic narcotic & sedative. children 1 month-2 years may incresed 0.004 mg/pound body weight (0.02 mL).Intraoperative Adult 0.1 mg (0.5 mL) IV. May repeat at intervals of 2-3 mins. Children 0.002 mg/pound body weight (0.01 mL) IV. Max: 0.1 mg (0.5 mL)/dose. May repeat at intervals of 2-3 minsReversal of neuromuscular blockade Adult & children 0.2 mg (1 mL) IV for each 1 mg of neostigmine or 5 mg of pyridostigmine. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Contraindications  | In management of peptic ulcer, may be C/I in glaucoma; obstructive uropathy; achalasia; pyloroduodenal stenosis; paralytic ileus; intestinal atony in the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Inj Newborn infant <1 mth.                                                                                                                                                                                                                |
| Adverse Effects    | Dry mouth; urinary hesitancy & retention; blurred vision. Increased ocular tension; tachycardia; palpitations; decreased sweating, loss of taste, headache, nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; severe allergic reaction, drug idiosyncrasies; urticaria; mental confusion.                                                                                                                                                                                                  |
| Pregnancy          | No (Limited) Human Data â€“ No Relevant Animal Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

